» Articles » PMID: 2406902

Induction of Chronic Myelogenous Leukemia in Mice by the P210bcr/abl Gene of the Philadelphia Chromosome

Overview
Journal Science
Specialty Science
Date 1990 Feb 16
PMID 2406902
Citations 497
Authors
Affiliations
Soon will be listed here.
Abstract

In tumor cells from virtually all patients with chronic myelogenous leukemia, the Philadelphia chromosome, a fusion of chromosomes 9 and 22, directs the synthesis of the P210bcr/abl protein. The protein-tyrosine kinase activity and hybrid structure of P210bcr/abl are similar to the oncogene product of the Abelson murine leukemia virus, P160gag/v-abl, which induces acute lymphomas. To determine whether P210bcr/abl can induce chronic myelogenous leukemia, murine bone marrow was infected with a retrovirus encoding P210bcr/abl and transplanted into irradiated syngeneic recipients. Transplant recipients developed several hematologic malignancies; prominent among them was a myeloproliferative syndrome closely resembling the chronic phase of human chronic myelogenous leukemia. Tumor tissue from diseased mice harbored the provirus encoding P210bcr/abl. These results demonstrate that P210bcr/abl expression can induce chronic myelogenous leukemia. Retrovirus-mediated expression of the protein provides a murine model system for further analysis of the disease.

Citing Articles

T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy.

Hsu M, Willimsky G, Hansmann L, Blankenstein T Front Immunol. 2025; 16:1518691.

PMID: 39931057 PMC: 11807957. DOI: 10.3389/fimmu.2025.1518691.


Significance of Somatic Mutation Profiling in CML Beyond BCR-ABL: A Retrospective Study of the Indian Population.

Chaudhary P, Chaudhary S, Patel F, Patel S, Patel D, Patel L Indian J Hematol Blood Transfus. 2025; 41(1):10-22.

PMID: 39917513 PMC: 11794774. DOI: 10.1007/s12288-024-01808-9.


Exploration of degrons and their ability to mediate targeted protein degradation.

Harris Jr T, Trader D RSC Med Chem. 2025; .

PMID: 39867589 PMC: 11758578. DOI: 10.1039/d4md00787e.


The CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapy.

Decroos A, Meddour S, Demoy M, Piccirilli N, Rousselot P, Nicolini F Front Immunol. 2024; 15:1473139.

PMID: 39620210 PMC: 11604645. DOI: 10.3389/fimmu.2024.1473139.


Cytosolic delivery of monobodies using the bacterial type III secretion system inhibits oncogenic BCR: ABL1 signaling.

Lebon C, Grossmann S, Mann G, Lindner F, Koide A, Koide S Cell Commun Signal. 2024; 22(1):500.

PMID: 39415233 PMC: 11483992. DOI: 10.1186/s12964-024-01874-6.